Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Open-label Long-term Extension Treatment with Intra-Erythrocyte Dexamethasone Sodium Phosphate in Ataxia Telangiectasia
2018-000338-36Phase 3Completed
- Sponsor
- EryDel S.p.A.
- Start
- Apr 2018
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of dexamethasone sodium phosphate in ataxia-telangiectasia (AT), sponsored by EryDel S.p.A. Primary endpoints: Change in Modified International Cooperative Ataxia Rating Scale (ICARS) total score and Long-term safety and tolerability of EDS-EP. Started Apr 2018; status: completed.
02
Drugs
dexamethasone sodium phosphate
03
Conditions
ataxia-telangiectasia (AT)
Beyond the preview
Go deeper on 2018-000338-36.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2018-000338-36.